Physicochemical Properties
| Molecular Formula | C34H58N8O11 |
| Molecular Weight | 754.87 |
| CAS # | 855790-98-6 |
| Appearance | Typically exists as solid at room temperature |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | DPP-4 |
| ln Vitro | SGP8 (0,100 and 500 µM; 24 h) has regulatory effects on lipid metabolism, inflammation and fibrosis[1]. SGP8 (0,100 and 500 µM; 24 h) significantly increased serum GLP-1 levels in vivo and SGP8 has inhibitory activity against DPP4[1]. Real Time qPCR[1] Cell Line: L02 cells Concentration: 0,100 and 500 µM Incubation Time: 24h Result: Improved the mRNA expression of lipid metabolism genes related to Cd36, Scd1, Cpt1 and Pparα and significantly reduced the mRNA expression of inflammatory genes Tnfα, Il-1β, and Ccl5. |
| ln Vivo | SGP8 (15 mg/kg, intraperitoneally injected once a day for 4 weeks) alleviates MCD-induced steatohepatitis in mice[1]. SGP8 (15 mg/kg, intraperitoneally injected once a day for 8 weeks) alleviates HFD-induced liver damage and metabolic disorders in mice[1]. |
| Cell Assay |
Western Blot Analysis[1] Cell Types: L02 Tested Concentrations: 0,100 and 500 µM Incubation Duration: 24h Experimental Results: Reduced the expression of lipid metabolism genes related to CD36, FAS, and SREBP-1 compared to the 1 mM PO model group. Immunofluorescence[1] Cell Types: LX2 Tested Concentrations: 0 and 500 µM Incubation Duration: 24h Experimental Results: Reduced effectively TGFβ1-induced expression of α-SMA and Collagen I protein expression. |
| Animal Protocol |
Animal/Disease Models:Healthy 7-week-old male C57BL/6J mice (22 and 27 g)[1] Doses: 15 mg/kg; everydays for four weeks Route of Administration: i.g. Experimental Results: Did not reverse the weight loss of mice caused by the MCD diet. Reduces the ratio of liver weight to body weight, as well as liver TG and TC content. Reduces the activities of ALT and AST in the serum of MCD dietinduced NASH mice. Improved liver fibrosis in MCD diet-induced NASH mice. |
| References |
[1]. Peng Ma,et al. IAVPGEVA: Orally Available DPP4-Targeting Soy Glycinin Derived Octapeptide with Therapeutic Potential in Nonalcoholic Steatohepatitis.Journal of Agricultural and Food Chemistry. 2024, 72, 13, 7167–7178. |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3247 mL | 6.6237 mL | 13.2473 mL | |
| 5 mM | 0.2649 mL | 1.3247 mL | 2.6495 mL | |
| 10 mM | 0.1325 mL | 0.6624 mL | 1.3247 mL |